Want the full evidence writeup?
The Stack Protocol builds four complete goal stacks — Energy, Focus, Sleep, Longevity — with exact doses, timing, budget tiers, and a 30-day rollout plan, graded with the same evidence framework behind this page.
EPA and DHA: Distinct Mechanisms, Not Interchangeable
EPA (Eicosapentaenoic Acid, C20:5n-3)
EPA is an omega-3 fatty acid with 20 carbons and 5 double bonds. Its primary mechanisms:
- Competitive AA inhibition: EPA and arachidonic acid (AA, C20:4n-6) compete for the same enzymatic pathways — COX (cyclooxygenase) and LOX (lipoxygenase). When EPA occupies COX instead of AA, it generates 3-series prostaglandins and 5-series leukotrienes (far less pro-inflammatory than the 2-series and 4-series respectively produced from AA). Higher tissue EPA → less pro-inflammatory eicosanoid production from the same COX/LOX enzymes.
- E-series resolvin precursor: Aspirin-acetylated COX-2 converts EPA to 18-HEPE, which is then converted by 5-LOX to E-series resolvins (RvE1, RvE2). These resolvins actively resolve inflammation — stopping neutrophil recruitment, triggering macrophage clearance of apoptotic cells, and signaling return to tissue homeostasis. This is not anti-inflammation (suppressing the response) but pro-resolution (actively completing it).
- Membrane effects: EPA incorporates into phospholipid membranes, reducing membrane fluidity and modulating signaling through lipid rafts — affecting NF-κB activation and inflammatory gene expression.
DHA (Docosahexaenoic Acid, C22:6n-3)
DHA has 22 carbons and 6 double bonds — the highest degree of unsaturation of any common fatty acid, giving it exceptional membrane flexibility. Its primary roles:
- Neuronal membrane structure: DHA comprises ~40% of fatty acids in the brain gray matter phospholipids and ~50% of photoreceptor outer segment phospholipids. Its extreme unsaturation allows rapid conformational changes needed for rhodopsin activation and synaptic vesicle fusion. DHA deficiency during neurodevelopment produces lasting cognitive deficits.
- D-series resolvin and protectin precursor: DHA is converted via 15-LOX to D-series resolvins (RvD1–D6) and protectins (PD1, neuroprotectin D1). Neuroprotectin D1 is particularly important in the brain — it protects neurons from oxidative stress, reduces amyloid-beta toxicity, and may be a mediator of DHA's neuroprotective effects.
- Triglyceride lowering: Both EPA and DHA lower triglycerides via reduced VLDL production from the liver. At 4g/day, EPA alone (REDUCE-IT) lowers triglycerides by ~19%; EPA+DHA combinations lower triglycerides by 20–30%.
| Trial | Drug / Dose | Result | Controversy |
|---|---|---|---|
| REDUCE-IT 2019 (Bhatt, NEJM, N=8,179) | Icosapentaenoic acid ethyl ester (EPA only) 4g/day; mineral oil placebo | MACE −25%; CV death −20%; cardiac arrest −48%; triglycerides −19% | Mineral oil placebo raised LDL-C and hsCRP in controls, inflating benefit estimate. Magnitude of benefit may be modestly overstated but directional effect is likely real |
| STRENGTH 2020 (Nicholls, JAMA, N=13,078) | EPA+DHA carboxylic acid (Epanova) 4g/day; corn oil placebo | No MACE benefit; stopped early for futility; triglycerides −19% | Corn oil placebo may have had cardiac benefit (oleic acid), masking drug effect. EPA+DHA combination may dilute EPA's specific effects. Population had lower baseline CV risk than REDUCE-IT |
| ORIGIN 2012 (NEJM, N=12,536) | EPA+DHA 1g/day in T2D + prediabetes | No cardiovascular benefit at 1g/day | Likely underdosed; consistent with dose-dependency hypothesis — cardiovascular benefit may require ≥2–3g EPA/day to achieve meaningful AA:EPA ratio shift |
| VITAL 2019 (Manson, NEJM, N=25,871) | EPA+DHA 1g/day in general population | Primary MACE non-significant; post-hoc: significant benefit in fish-non-consumers (biggest benefit where baseline omega-3 status lowest) | Supports threshold effect — supplementation benefits people with low baseline omega-3 status; less benefit when omega-3 index already adequate |
Omega-3 Protocol: Dose, Form, Testing, and Fish vs Algae
- Test before you supplement: The Omega-3 Index (OmegaQuant, Boston Heart, Cleveland HeartLab) measures EPA+DHA as % of total RBC fatty acids. A value below 4% is high-risk; 8–12% is the target associated with cardiovascular protection. This test costs $50–100 and directs dosing: someone at 3% needs very different supplementation than someone already at 7%. Without knowing your baseline, you may over- or under-supplement.
- Dose for cardiovascular indication: REDUCE-IT used 4g/day EPA (as ethyl ester). To achieve similar plasma EPA levels with triglyceride fish oil, you need approximately 3–4g EPA/day of combined EPA+DHA. Start with 2g/day and test the Omega-3 Index at 3 months; increase to 3–4g/day if index is below 8%. For general health maintenance, 1–2g/day EPA+DHA maintains the index in most people already consuming some fatty fish.
- EPA vs DHA prioritization: For cardiovascular protection, EPA-dominant or EPA-only products have the trial data (REDUCE-IT). For brain health, cognitive function, or neuroinflammation, DHA-dominant products are mechanistically appropriate. For general supplementation without specific indication, a balanced EPA+DHA product (2:1 or 1:1 ratio) covering both needs is reasonable. Algae oil provides DHA-dominant omega-3s — ideal for vegetarians and for brain/cognitive goals.
- Fish oil vs algae oil: Fish don't make EPA/DHA — they accumulate it from algae they eat. Going directly to algae oil eliminates PCB/heavy metal contamination risk, reduces oxidation (fresh algae oil oxidizes less than processed fish oil), and is sustainable. Algae oil is DHA-dominant (~300mg DHA, ~150mg EPA per serving); fish oil is typically more balanced. For vegetarians/vegans or those with fish allergy/aversion, algae oil is the correct choice. For EPA-dominant cardiovascular dosing, fish oil concentrate (IFOS 5-star certified) provides higher EPA per gram.
- Oxidation — the quality killer: Oxidized fish oil produces malondialdehyde and other lipid oxidation products that may negate health benefits and cause GI upset. Signs of oxidized oil: fishy odor (fresh fish oil should smell like the ocean, not "fishy"), burping that tastes of rancid fat, dark yellow or brown color. Store in the refrigerator after opening, buy in dark bottles, and consume within 3 months of opening. IFOS (International Fish Oil Standards) certification verifies oxidation levels, heavy metals, and EPA/DHA label accuracy.
High-Quality Omega-3 Supplements — IFOS Certified Fish Oil and Algae Oil
View IFOS-Certified Omega-3 Supplements on Amazon →
Look for IFOS 5-star certification on the label or manufacturer website — this verifies EPA/DHA content matches label claims, heavy metals are below limits, and oxidation (TOTOX value) is acceptable. Nordic Naturals, Thorne, and Carlson are consistently IFOS-certified brands. For algae oil: Vegetology Opti3, Nordic Naturals Algae Omega. For high-dose EPA targeting (2–4g EPA/day), concentrated ethyl ester products provide more EPA per capsule with fewer capsules needed vs triglyceride form.